公司运营状况 - RxSight公司面临采用挑战和结构性问题导致销售和利用率下降 [1] - 公司管理层高估了产品需求 [1] - 公司不太可能实现其先前发布的2025财年财务指引 [1] 信息披露问题 - 被告在2024年11月7日至2025年7月8日期间发布 materially false and/or misleading statements [1] - 公司未能披露重大不利信息 [1] - 公司关于业务运营和前景的积极陈述缺乏合理依据 [1] 法律诉讼进展 - 集体诉讼登记截止日期为2025年9月22日 [2] - 股东可登记参与诉讼无需承担任何费用 [2] - 牵头原告申请截止日期为2025年9月22日 [2]

诉讼背景 - 证券律师事务所Bleichmar Fonti & Auld LLP对RxSight公司及高管提起集体诉讼 指控其违反联邦证券法 [1] - 诉讼依据为《1934年证券交易法》第10(b)条和第20(a)条 代表购买RxSight证券的投资者主张权利 [2] - 案件由美国加州中区联邦法院受理 案件编号25-cv-01596 投资者申请担任首席原告截止日期为2025年9月22日 [2] 公司业务 - RxSight专注于制造和销售用于白内障手术的光可调节人工晶体(LAL)及配套资本设备 [3] - 公司核心产品LAL可通过无创光治疗进行术后定制 使用光传输设备(LDD)调整晶体形状和屈光度以优化患者视力 [3] 指控内容 - 公司在相关期间未披露产品存在"采用挑战" 反而宣扬其LAL和LDD销售表现强劲 [4] - 实际情况是RxSight自2024年起就出现LAL使用率增长放缓的情况 [4] 股价影响 - 2025年4月3日盘前 公司以2024年下半年市场"疲软"为由下调全年收入预期 股价单日下跌38% 从26.12美元/股跌至16.21美元/股 [5] - 2025年7月8日 公司再次下调收入预期 归因于"2024年首次出现的LAL使用率增长放缓"及"过去几个季度的采用挑战" 股价次日下跌38% 从12.79美元/股跌至7.95美元/股 [6]

NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025, both dates inclusive (the “Class Period”, of the important September 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased RxSight securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT ...

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of RxSight, Inc. (NASDAQ: RXST)?Did you purchase your shares between November 7, 2024 and July 8, 2025, inclusive?Did you lose money in you ...

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to ...

NEW YORK, Aug. 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to ...

诉讼背景 - 证券律师事务所Bleichmar Fonti & Auld LLP对RxSight公司及高管提起集体诉讼 指控其违反联邦证券法 [1] - 诉讼依据《1934年证券交易法》第10(b)条和第20(a)条提出 代表购买RxSight证券的投资者 [2] - 案件由美国加州中区联邦地区法院审理 案件编号25-cv-01596 [2] 公司业务 - RxSight从事白内障手术用可调节人工晶状体及相关资本设备的制造销售 [3] - 核心产品为光可调节晶状体(LAL) 可通过无创光治疗在术后根据患者需求定制视觉优化 [3] - 治疗使用光传输设备(LDD)调整晶状体形状和屈光度 [3] 指控内容 - 公司在相关期间未披露产品存在的"采用挑战"问题 [4] - 实际自2024年起已出现LAL使用率增长放缓的情况 [4] 股价影响 - 2025年4月3日开盘前 公司以2024年下半年市场"疲软"为由下调全年收入预测 [5] - 消息导致股价从26.12美元/股跌至16.21美元/股 单日跌幅达38% [5] - 2025年7月8日 公司再次下调收入预测 归因于"2024年首次出现的LAL使用率增长放缓"和"过去几个季度的采用挑战" [6] - 股价从12.79美元/股跌至7.95美元/股 单日跌幅达38% [6]

NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in RxSight, Inc. ("RxSight, Inc." or the "Company") (NASDAQ: RXST) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of RxSight, Inc. investors who were adversely affected by alleged securities fraud between November 7, 2024 and July 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/rxsight-inc-lawsuit-submis ...

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in RxSight, Inc. ("RxSight, Inc." or the "Company") (NASDAQ: RXST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of RxSight, Inc. investors who were adversely affected by alleged securities fraud between November 7, 2024 and July 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/rxsight-inc-lawsuit- ...

公司动态 - 公司计划参加2025年9月8日在纽约市举行的摩根士丹利医疗健康会议 [1] - 管理层将于太平洋时间上午7:45/东部时间上午10:45进行演讲 [2] - 提供演讲的实时及存档网络直播链接 https://investors.rxsight.com/ [2] 业务专长 - 专注于为白内障术后患者提供高质量定制视力解决方案的眼科医疗器械公司 [1][3] - 拥有全球首款且唯一商业化的术后可调节人工晶体（IOL）技术 [3] - 核心技术系统包括：可调节晶体（LAL®/LAL+®）、光传输设备（LDD™）及配套附件 [3] 技术优势 - 光可调节晶体系统支持术后视力调整 [3] - 允许医生在白内障手术后实现视力定制化优化 [3]